Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Camizestrant with Midazolam and Carbamazepine in Healthy Women
NCT06547164Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of camizestrant in estrogen receptor-positive breast cancer (ER+) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity of midazolam at Day 8, Area under concentration curve from time 0 to the last quantifiable concentration of midazolam at Day 8 and 4 more. Started Aug 2024; status: completed.
02
Drugs
camizestrant
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT06547164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547164.